+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Market Spotlight: Obesity

  • ID: 4846137
  • Report
  • September 2020
  • Region: Global
  • 55 pages
  • Datamonitor Healthcare
1 of 3

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • AstraZeneca
  • Boehringer Ingelheim
  • Gubra
  • Novo Nordisk
  • MORE
This Market Spotlight report covers the Obesity market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, key upcoming and regulatory events, probability of success, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways
  • The publisher estimates that in 2017, there were approximately 681.3 million prevalent cases of obesity in adults (aged 20+ years) worldwide, and expects that number to increase to 762.9 million prevalent cases by 2026.
  • In the same year, The publisher estimates that there were 126.6 million prevalent cases of obesity in children and adolescents (aged 5–19 years) worldwide, and expects that number to increase to 134.0 million prevalent cases by 2026.
  • Prevalence proportions are highest in Northern America and lowest in Asia. The approved drugs in the obesity space target gastric lipase, dopamine, norepinephrine (noradrenaline), dopamine reuptake, norepinephrine (noradrenaline) reuptake/transporter, opioid receptors, GABA-A receptor, and glucagon-like peptide-1 (GLP-1) receptor. The majority of marketed drugs are administered via the oral route, with one product being available in a subcutaneous formulation.
  • The majority of industry-sponsored drugs in active clinical development for obesity are in Phase I, with two drugs in Phase III. Therapies in development for obesity focus on a wide variety of targets, with the subcutaneous route being the most common method of delivery.
  • High-impact upcoming events for drugs in the obesity space comprise an expected PDUFA date, a decentralized EU approval, and an estimated EU patent expiration for Qsymia.
  • The overall likelihood of approval of a Phase I obesity asset is 2.6%, and the average probability a drug advances from Phase III is 62.5%. Drugs, on average, take 8.6 years from Phase I to approval, compared to 8.9 years in the overall metabolic space.
  • The distribution of clinical trials across Phase I–IV indicates that the majority of trials for obesity have been in the early and midphases of development, with 66% of trials in Phase I–II, and 34% in Phase III–IV.
  • The US has a substantial lead in the number of obesity clinical trials globally. The UK leads the major European markets, while Japan has the top spot in Asia.
  • Clinical trial activity in the obesity space is dominated by completed trials. AstraZeneca has the highest number of completed clinical trials for obesity, with 78 trials.
  • Novo Nordisk leads industry sponsors with the highest overall number of clinical trials for obesity, followed by AstraZeneca.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • AstraZeneca
  • Boehringer Ingelheim
  • Gubra
  • Novo Nordisk
  • MORE
Overview

Key Takeaways

Disease Background

Treatment
  • Medications
  • Surgery
Epidemiology

Marketed Drugs

Pipeline Drugs

Recent Events and Analyst Opinion
  • AM833 for Obesity (June 18, 2020)
  • Ozempic for Obesity (June 12, 2020)
  • Ozempic for Obesity (June 4, 2020)
  • Ozempic for Obesity (May 13, 2020)
  • Tesomet for Obesity (April 22, 2020)
  • Efpeglenatide for Obesity (December 10, 2019)
  • Efinopegdutide for Obesity (July 3, 2019)
  • NS-0200 for Obesity (June 8, 2019)
  • PLENITY for Obesity (April 14, 2019)
  • PLENITY for Obesity (March 25, 2019)
Key Upcoming Events

Key Regulatory Events
  • MAAs Under Review/Rhythm Files Setmelanotide
  • EMA Considers Fast-Tracking Rhythm’s Insatiable Hunger and Obesity Disorders Drug
  • Three Fast Track Drugs Stand Out In Flurry Of Submissions
  • FDA Requests Belviq Be Pulled From The US Market Due To Cancer Risk
  • Preparing For Qsymia Launch In Korea
Probability of Success

Licensing and Asset Acquisition Deals
  • CMS Pays $35m For China Rights To Gelesis Obesity Therapy
  • Novo/Fauna Partnership Includes Options To Resulting Drug Candidates
  • Novo Nordisk Enters Its First Strategic RNAi Pact
Clinical Trial Landscape
  • Sponsors by status
  • Sponsors by phase
  • Recent events
Bibliography
  • Prescription information
Appendix

List of Figures
  • Figure 1: Trends in prevalent cases of obesity in adults, 2017–26
  • Figure 2: Overview of pipeline drugs for obesity in the US
  • Figure 3: Pipeline drugs for obesity, by company
  • Figure 4: Pipeline drugs for obesity, by drug type
  • Figure 5: Pipeline drugs for obesity, by classification
  • Figure 6: AM833 for Obesity (June 18, 2020): Phase I - w/Semaglutide / Phase II - 4433
  • Figure 7: AM833 for Obesity (June 18, 2020): Phase I - w/Semaglutide / Phase II - 4433
  • Figure 8: Ozempic for Obesity (June 12, 2020): Phase IIIa - STEP 2 (Overweight/obese diabetics), Phase IIIa - STEP 3 (Maximizing Weight Loss)
  • Figure 9: Ozempic for Obesity (June 4, 2020): Phase IIIa - STEP 1 (Weight Loss)
  • Figure 10: Ozempic for Obesity (May 13, 2020): Phase IIIa - STEP 4 (Maintained Weight Loss)
  • Figure 11: Tesomet for Obesity (April 22, 2020): Phase IIa - Hypothalamic Obesity (Denmark)
  • Figure 12: NS-0200 for Obesity (June 8, 2019): Phase II - NS-WM-01
  • Figure 13: Key upcoming events in obesity
  • Figure 14: Probability of success in the obesity pipeline
  • Figure 15: Clinical trials in obesity
  • Figure 16: Top 10 drugs for clinical trials in obesity
  • Figure 17: Top 10 companies for clinical trials in obesity
  • Figure 18: Trial locations in obesity
  • Figure 19: Obesity trials status
  • Figure 20: Obesity trials sponsors, by phase
List of Tables
  • Table 1: Prevalent cases of obesity in adults, 2017–26
  • Table 2: Prevalent cases of morbid obesity in adults, 2017–26
  • Table 3: Prevalent cases of obesity in children and adolescents, 2017–26
  • Table 4: Prevalence proportions of obesity and morbid obesity, 2017
  • Table 5: Marketed drugs for obesity
  • Table 6: Pipeline drugs for obesity in the US
  • Table 7: AM833 for Obesity (June 18, 2020)
  • Table 8: Ozempic for Obesity (June 12, 2020)
  • Table 9: Ozempic for Obesity (June 4, 2020)
  • Table 10: Ozempic for Obesity (May 13, 2020)
  • Table 11: Tesomet for Obesity (April 22, 2020)
  • Table 12: Efpeglenatide for Obesity (December 10, 2019)
  • Table 13: Efinopegdutide for Obesity (July 3, 2019)
  • Table 14: NS-0200 for Obesity (June 8, 2019)
  • Table 15: PLENITY for Obesity (April 14, 2019)
  • Table 16: PLENITY for Obesity (March 25, 2019
Note: Product cover images may vary from those shown
3 of 3
  • AstraZeneca
  • Boehringer Ingelheim
  • Gubra
  • Novo Nordisk
Note: Product cover images may vary from those shown
Adroll
adroll